Search the Newsreel

Exicure Inc (XCUR) Stock News Today

This page provides an overview of Exicure Inc (XCUR) stock, including its current price, market cap, and a note that more news is coming soon. The stock closed at $1.345, down 0.74% on August 7th. It also lists various financial and analytical tools available …

XCUR|Exicure Inc|Price:1.345|Chg%:-0.010

Exicure to settle $1M clinical milestone with GPCR Therapeutics via stock issuance in August 2026

Exicure, Inc. will settle a $1 million clinical milestone payment to GPCR Therapeutics by issuing 172,058 shares of common stock, valued at $5.81 each, in August 2026. This payment follows the completion of a Phase 2 trial for Burixafor and the submission of its …

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

Exicure, Inc. announced its plan to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. during August 2026. This issuance will settle a $1.0 million clinical milestone payment obligation related to the completion of a Phase 2 clinical trial. The equity issuance, …

XCUR Looks 231.6% Overvalued on GF Value™

Exicure Inc (NASDAQ: XCUR) is issuing shares for a milestone payment related to a successful Phase 2 clinical trial, yet its stock appears significantly overvalued. The company has a GF Score™ of 32/100, reflecting weak profitability and financial strength, and its GF Value™ estimates …

Exicure to issue shares to settle $1M clinical milestone payment By Investing.com

Exicure (NASDAQ:XCUR) will issue 172,058 shares of common stock to GPCR Therapeutics, Inc. to settle a $1 million clinical milestone payment. This payment was triggered by the completion and FDA submission of the Phase 2 clinical trial for Burixafor (GPC-100). The move allows Exicure …

Exicure Class Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against Exicure, Inc. (NASDAQ: XCUR) and encouraging investors who lost over $100,000 to seek lead plaintiff status by the February 11, 2022 deadline. The lawsuit alleges that Exicure made misleading statements about its preclinical program for …

Exicure Update

Faruqi & Faruqi, LLP is investigating potential claims against Exicure, Inc. (NASDAQ: XCUR) and has set a lead plaintiff deadline of February 11, 2022, for investors who suffered losses exceeding $100,000. The investigation stems from alleged improprieties in Exicure's preclinical program for Friedreich's ataxia, …

Exicure Inc (XCUR) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Exicure Inc (XCUR) as of July 30, 2026, assigning it a financial score of 4.76, which ranks 378 out of 384 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low …

Exicure Inc (XCUR) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Exicure Inc (XCUR), noting its current valuation score is 8.93, ranking it 38 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -2.04 and mentions that relevant data …

Exicure Inc (XCUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Exicure Inc (XCUR). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays basic stock information such as the current …

Exicure Inc (XCUR) Institutional Confidence

This article examines the institutional confidence in Exicure Inc (XCUR) based on data updated on July 27, 2026. It highlights institutional shareholding and shareholder activity, detailing which institutions hold shares, the number of shares, and changes in their holdings. Key institutional investors include Exicure …

Exicure Inc (XCUR) Cash Flow

This article provides a comprehensive overview of Exicure Inc's (XCUR) cash flow statements, including operating, investing, and financing activities, presented in a detailed, quarterly, and annual format. It highlights key financial figures such as net income, capital expenditures, and free cash flow, explaining their …

Exicure Inc (XCUR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the historical dividend payouts and stock splits for Exicure Inc (XCUR). Over the past five years, the company has not distributed any dividends. However, it lists several merger-related stock splits, including multiple 5-to-1 splits scheduled for August 26, 2024, …

Exicure Inc (XCUR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Exicure Inc (XCUR), outlining major shareholders and institutional holdings as of various reporting periods. It lists top individual and corporate shareholders, their proportion, and changes in their holdings, alongside institutional ownership statistics and related ETF information.

XCUR|Exicure Inc|Price:1.750|Chg%:-0.010

The article provides a comprehensive stock analysis of Exicure Inc (XCUR) by TradingKey. It highlights the company's relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The analysis also notes high institutional ownership, a likely downward trend …

Exicure Q2 2022 Earnings: Pre-Revenue Biotech Misses EPS Estimates Amid Stock Uptick - Revenue Growth Outlook

Exicure Inc (XCUR) Income Statement

This article provides the quarterly and annual income statements for Exicure Inc (XCUR), detailing its financial performance over several years. It includes key financial metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income, alongside year-over-year percentage changes. The article …

XCUR stock trades on limited evidence as Exicure waits for filings

Exicure Inc. (XCUR) stock is currently trading with limited market drivers, with the company's investor relations site being the primary source of information. The article emphasizes that without recent filings, fresh market data, or updated operational figures, any analysis must remain tightly factual and …

Exicure Inc (XCUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Exicure Inc (XCUR), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that XCUR currently has a price momentum score of 6.17 and is trading within a range, with indicators giving …

Exicure, Inc. (XCUR) holder Exicure HiTron regains 623,275 returned shares

Exicure HiTron Inc., a major shareholder of EXICURE, INC. (XCUR), has reported the acquisition of 623,275 common shares through a series of "code J" transactions between June 23 and July 8, 2026, each priced at $4.50. These shares were returned to Exicure HiTron due …

Form 13D/A EXICURE For: 17 July By Investing.com

This article announces the filing of Form 13D/A for EXICURE on July 17th. It is a brief administrative notice from Investing.com, providing no further details about the filing itself. The page includes general market data and related news not specific to the EXICURE filing.

Exicure HiTron boosts Exicure (XCUR) holding to 2.22M shares, 34.87%

Exicure HiTron Inc. has increased its beneficial ownership in Exicure, Inc. (XCUR) to 34.87%, holding 2,222,224 shares after amending previous share transfer transactions. This change resulted from five purchasers returning an aggregate of 623,277 Exicure shares to Exicure HiTron, with the reacquisition recorded by …